5 Free Dividend Stocks for 2022
Could these top payout stocks be part of the greatest wealth-creating tool in history?
Learn More.
Sophia Randolph, insider at ALX Oncology
Sophia Randolph Insider Alerts

Get notified the next time Sophia Randolph buys or sells ALX Oncology stock. Enter your email address below to get our daily insider buying and selling report.

Sophia Randolph Insider Information

Insider of ALX Oncology
Dr. Randolph has served as our Chief Medical Officer since June 2016 and a member of our board of directors since March 2021. Prior to joining us, she was with Pfizer Oncology Early and Late Development Groups from June 2008 to April 2016, where she served most recently as Executive Director, Oncology from June 2015 to April 2016. From June 2007 to May 2008, Dr. Randolph served as Director, Clinical Sciences, Oncology at Merck, a pharmaceutical company. She holds an A.B. in Biochemistry from Harvard University and an M.D. and a Ph.D. in Cellular and Molecular Biology from the University of Michigan. Dr. Randolph completed her oncology fellowship training at Seattle Cancer Care Alliance/Fred Hutchinson Cancer Research Center.

What is Sophia Randolph's net worth?

The estimated net worth of Sophia Randolph is at least $2.62 million as of September 10th, 2021. Dr. Randolph owns 163,302 shares of ALX Oncology stock worth more than $2,624,263 as of January 20th. This net worth estimate does not reflect any other investments that Dr. Randolph may own. Additionally, Dr. Randolph receives an annual salary of $938,500.00 as Insider at ALX Oncology. Learn More.

How old is Sophia Randolph?

Dr. Randolph is currently 53 years old. There are 5 older executives and no younger executives at ALX Oncology. The oldest executive at ALX Oncology is Dr. Corey S. Goodman, Independent Exec. Chairman, who is 69 years old. Learn More.

What is Sophia Randolph's salary?

As the Insider of ALX Oncology Holdings Inc., Dr. Randolph earned a total compensation package of $2,757,365.00 in 2020. Dr. Randolph earned a salary of $397,588.00, a bonus of $350,000.00, options awards of $1,818,862.00, non-equity compensation of $190,915.00, and no other miscellaneous compensation. The highest earning executive at ALX Oncology is Dr. Jaume Pons Ph.D., Pres, CEO & Director, who commands a salary of $1,280,000.00 per year.

How do I contact Sophia Randolph?

The corporate mailing address for Dr. Randolph and other ALX Oncology executives is 866 MALCOLM ROAD SUITE 100, BURLINGAME CA, 94010. ALX Oncology can also be reached via phone at 650-466-7125 and via email at [email protected]

Has Sophia Randolph been buying or selling shares of ALX Oncology?

Sophia Randolph has not been actively trading shares of ALX Oncology during the last ninety days. Most recently, Sophia Randolph sold 14,884 shares of the business's stock in a transaction on Monday, November 22nd. The shares were sold at an average price of $36.77, for a transaction totalling $547,284.68.

Who are ALX Oncology's active insiders?

ALX Oncology's insider roster includes Peter Garcia (CFO), Jaume Pons (CEO), and Sophia Randolph (Insider).

Are insiders buying or selling shares of ALX Oncology?

In the last twelve months, insiders at the sold shares 25 times. They sold a total of 798,252 shares worth more than $32,485,416.88. The most recent insider tranaction occured on December, 13th when Director Jason Lettmann sold 325,377 shares worth more than $8,902,314.72. Insiders at ALX Oncology own 58.2 % of the company.

Information on this page was last updated on 12/13/2021.

Sophia Randolph Insider Trading History at ALX Oncology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/22/2021Sell14,884$36.77$547,284.68View SEC Filing Icon  
10/11/2021Sell7,387$60.97$450,385.39View SEC Filing Icon  
9/10/2021Sell7,387$77.66$573,674.42163,302View SEC Filing Icon  
7/12/2021Sell7,387$54.90$405,546.30View SEC Filing Icon  
4/12/2021Sell7,387$59.43$439,009.41198,234View SEC Filing Icon  
3/10/2021Sell7,387$74.34$549,149.58207,227View SEC Filing Icon  
See Full Table

Sophia Randolph Buying and Selling Activity at ALX Oncology

This chart shows Sophia Randolph's buying and selling at ALX Oncology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

ALX Oncology Company Overview

ALX Oncology logo
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell; human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma; and HER2-expressing breast cancer. The company's pre-clinical products include SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer. ALX Oncology Holdings Inc. has a collaboration agreement with Merck for a Phase 2 trial evaluating ALX148 in combination with pembrolizumab with and without chemotherapy in patients with head and neck cancer; Zymeworks on a Phase 1 trial evaluating ALX148 with the HER2-targeting bispecific antibody zanidatamab in patients with advanced HER2-expressing breast cancer and other solid tumors; and Tallac Therapeutics for the development, manufacturing and commercialization of a novel class of cancer immunotherapeutics. It also has a license agreement with Selexis SA and Crystal Bioscience, Inc. The company was incorporated in 2015 and is based in Burlingame, California.
Read More

Today's Range

Now: $16.07
Low: $15.93
High: $17.92

50 Day Range

MA: $27.81
Low: $16.72
High: $46.39

2 Week Range

Now: $16.07
Low: $15.93
High: $89.04


614,771 shs

Average Volume

519,382 shs

Market Capitalization

$650.84 million

P/E Ratio


Dividend Yield



5 Free Dividend Stocks for 2022
Could these top payout stocks be part of the greatest wealth-creating tool in history?
Learn More.